KdT is the standard for early-stage science venture investing
We help founders and their companies
re-architect the world at a molecular level.
Writing the Physical Layer
Computation has improved our lives in remarkable ways, but the physical layer has remained largely unchanged.
We are often the first check into a company. Our unique model for early-stage investment allows us to have an outsized impact on the earliest stages of a venture.
Let’s Talk Molecules And Atoms
We can keep up. From bench to bedside to boardroom, our team has been on the front lines. Our understanding of the science and technology breakthroughs we’re evaluating is personal.
Chemistry and biology are the software of our physical world.
To solve some of the greatest challenges of our time, the best thing we can do is harness nature’s code. Thanks to next-generation sequencing and subsequent interpretation technologies, as well as AI and hyper-scale compute, we can now model and even alter nature’s source code to our liking.
Imagine a world in which humans and nature function in harmony.
We believe the greatest advancements of our lifetime will be the result of reprogramming chemistry and biology using creative technology platforms.
Our portfolio companies are commercializing science that is dramatically changing how the world works, from nano to whole earth scales.
Meet Our Team
The nicest VCs you’ve ever met
Guided by his passion for science, Cain founded KdT Ventures in 2017. A physician by training, Cain prefers to help create the future rather than practice in the past.
Learn more about Cain by clicking his Medium article below
Following years as a successful startup lawyer, Mack joined KdT to help identify and support its portfolio companies. Above all, Mack enjoys working with teams to accomplish only the most daunting of objectives.
Learn more about Mack by clicking his Medium article below
With a background in administration and team management, Ally is passionate about practicing organizational systems that empower and support KdT Ventures values and mission.
Learn more about Ally by clicking her Medium article below
Enroute to finishing his MD-PhD, Phil has been instrumental in the spin-out of three biotechnology companies. With a gifted eye for science, technology, and investing, Phil joined KdT in 2018.
Learn more about Phil by clicking his Medium article below
Venture For Science